Ocular Therapeutix, Inc.

Healthcare · Biotechnology · United States

Last price 6.97 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.53B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ...